76. Sci Rep. 2018 Feb 14;8(1):3036. doi: 10.1038/s41598-018-20832-0.Validating a breast cancer score in Spanish women. The MCC-Spain study.Dierssen-Sotos T(1)(2), Gómez-Acebo I(3)(4), Palazuelos C(4), Fernández-NavarroP(3)(5)(6), Altzibar JM(3)(7), González-Donquiles C(3)(8), Ardanaz E(3)(9)(10),Bustamante M(3)(11)(12)(13), Alonso-Molero J(4), Vidal C(14), Bayo-Calero J(15), Tardón A(3)(16), Salas D(17)(18), Marcos-Gragera R(19), Moreno V(3)(14)(20),Rodriguez-Cundin P(21), Vinyals GC(3)(11)(13)(22), Ederra M(3)(9)(10),Vilorio-Marqués L(8), Amiano P(3)(23), Pérez-Gómez B(3)(5)(6), AragonésN(3)(5)(6), Kogevinas M(3)(11)(13)(22)(24), Pollán M(3)(5)(6), Llorca J(3)(4).Author information: (1)CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.dierssent@unican.es.(2)University of Cantabria - IDIVAL, Santander, Spain. dierssent@unican.es.(3)CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.(4)University of Cantabria - IDIVAL, Santander, Spain.(5)Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.(6)Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puertade Hierro (IDIPHIM), Madrid, Spain.(7)Breast Cancer Screening Programme, Basque Health Department, Osakidetza,Spain.(8)Grupo de Investigación Interacciones Gen-Ambiente y Salud, Universidad deLeón, León, Spain.(9)Navarra Public Health Institute, Navarra, Spain.(10)IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.(11)ISGlobal Centre for Research in Environmental Epidemiology (CREAL),Barcelona, Spain.(12)Centre for Genomic Regulation (CRG), the Barcelona Institute of Science andTechnology, Barcelona, Spain.(13)Universitat Pompeu Fabra (UPF), Barcelona, Spain.(14)Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL,L'Hospitalet de Llobregat, Barcelona, Spain.(15)Complejo Hospitalario Universitario de Huelva, Centro de Investigación enSalud y Medio Ambiente (CYSMA), Universidad de Huelva, Huelva, Spain.(16)IUOPA, Universidad de Oviedo, Asturias, Spain.(17)Valencia Cancer and Public Health Area, FISABIO - Public Health, Valencia,Spain.(18)General Directorate Public Health, Valencian Community, Valencia, Spain.(19)Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan,Department of Health, Autonomous Government of Catalonia and DescriptiveEpidemiology, Genetics and Cancer Prevention Group [Girona Biomedical ResearchInstitute (IdIBGi)], Catalan Institute of Oncology, Girona, Spain.(20)Department of Clinical Sciences, Faculty of Medicine, University ofBarcelona, Barcelona, Spain.(21)University Hospital Marques de Valdecilla - IDIVAL, Santander, Spain.(22)IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain.(23)Public Health Division of Gipuzkoa, BioDonostia Research Institute, SanSebastian, Spain.(24)School of Public Health, Athens, Greece.A breast-risk score, published in 2016, was developed in white-American womenusing 92 genetic variants (GRS92), modifiable and non-modifiable risk factors.With the aim of validating the score in the Spanish population, 1,732 breastcancer cases and 1,910 controls were studied. The GRS92, modifiable andnon-modifiable risk factor scores were estimated via logistic regression. SNPswithout available genotyping were simulated as in the aforementioned 2016 study. The full model score was obtained by combining GRS92, modifiable andnon-modifiable risk factor scores. Score performances were tested via the areaunder the ROC curve (AUROC), net reclassification index (NRI) and integrateddiscrimination improvement (IDI). Compared with non-modifiable and modifiablefactor scores, GRS92 had higher discrimination power (AUROC: 0.6195, 0.5885 and0.5214, respectively). Adding the non-modifiable factor score to GRS92 improvedpatient classification by 23.6% (NRI = 0.236), while the modifiable factor score only improved it by 7.2%. The full model AUROC reached 0.6244. A simulation studyshowed the ability of the full model for identifying women at high risk forbreast cancer. In conclusion, a model combining genetic and risk factors can beused for stratifying women by their breast cancer risk, which can be applied toindividualizing genetic counseling and screening recommendations.DOI: 10.1038/s41598-018-20832-0 PMCID: PMC5813036PMID: 29445177 